EGFR and non-small cell lung carcinoma: The landmark ADAURA study (18) comparing a three-year course of adjuvant osimertinib versus placebo in completely resected stage IB to IIIA EGFR-mutant NSCLC demonstrated an early advantage in disease free survival of 89% vs 52% at 24 months with an overall hazard ratio (HR) 0.2 (99% CI, 0.14 to 0.30).